EU/3/17/1909

About

On 23 August 2017, orphan designation (EU/3/17/1909) was granted by the European Commission to Vaximm GmbH, Germany, for Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2 (also known as VXM01) for the treatment of glioma.

The sponsor’s address was updated in November 2018 and in March 2021.

Key facts

Active substance
Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2
Medicine name
-
Disease / condition
Treatment of glioma
Date of first decision
23/08/2017
Outcome
Positive
EU designation number
EU/3/17/1909

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Vaximm GmbH
Landteilstrasse 24
Lindenhof
Mannheim
Baden-Wuerttemberg 68163
Germany
Tel. +49 6218 35968710
E-mail: info@vaximm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating